Close Menu

Which sequencing platform will win the race to the 30X, $1,000 genome? That's what Keith Robison at Omics! Omics! wants to know. Of all the existing platforms, two are close to what Robison calls the "arbimagical" goal — a goal which is arbitrary but has achieved a magical aura from being repeated so much. ABI's SOLiD 4 platform has been said to generate a $6,000 genome, and the SOLiD 4 hq upgrade is planned for this fall with a target of delivering a $3,000 genome, Robison says.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Two COVID-19 vaccine developers have released their trial protocols to build public trust, the New York Times reports.

A new analysis finds the rapid COVID-19 test from DnaNudge to be highly accurate, Reuters reports.

In Science this week: global citizens' assembly on genome-editing technologies proposed, epigenetic markers predict metformin response, and more.

According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.